Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.88 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.88 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | DRD1 | P21728 | 2/20 | 0.67 |
| ▸ | DRD4 | P21917 | 2/20 | 0.67 |
| ▸ | DRD3 | P35462 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383587 | 1.00 | ADRB2 (0.88) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL14221484 | 0.91 | ADRB2 (0.77) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL5127959 | 0.89 | ADRB2 (0.87) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL244696 | 0.89 | ADRB2 (0.80) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL4889160 | 0.89 | ADRB2 (0.80) | ADRB2ADRB1DRD2DRD1DRD4 | |
| Acetic Acid SCHEMBL5120379 | 0.86 | ADRB2 (0.81) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL4895143 | 0.85 | ADRB2 (0.66) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL17074684 | 0.84 | ADRB2 (0.71) | ADRB2ADRB1 | |
| SCHEMBL17074685 | 0.84 | ADRB2 (0.71) | ADRB2ADRB1 | |
| SCHEMBL17074683 | 0.84 | ADRB2 (0.71) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402673-B2 | Diamine β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-22 | — | — | US | claimed |
| US-20080039495-A1 | Diamine Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-02-14 | — | — | US | claimed |
| US-20050272769-A1 | Diamine beta2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2005-12-08 | — | — | US | claimed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-108026080-B | Pyrazolyl-substituted heteroaryl compounds and their use as medicaments | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-110713489-A | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-7402673-B2 | Diamine β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402673-B2 | Diamine β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7402673-B2 | Diamine β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080039495-A1 | Diamine Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-02-14 | — | — | US | disclosed |
| US-20080039495-A1 | Diamine Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-02-14 | — | — | US | disclosed |
| US-20080039495-A1 | Diamine Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-02-14 | — | — | US | disclosed |
| WO-2007134964-A1 | NOVEL MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135024-A1 | NEW LONG-ACTING DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-29 | — | — | WO | disclosed |
| US-20050272769-A1 | Diamine beta2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272769-A1 | Diamine beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD2 53/4885 |
| US-20080039495-A1 | Diamine Beta2 Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD2 53/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | ADRB2 1410/4885ADRB1 887/4885DRD2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.